NASDAQ:LSTA Lisata Therapeutics (LSTA) Stock Price, News & Analysis $2.40 -0.03 (-1.40%) As of 01:06 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Lisata Therapeutics Stock (NASDAQ:LSTA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Lisata Therapeutics alerts:Sign Up Key Stats Today's Range$2.34▼$2.4450-Day Range$2.11▼$2.9652-Week Range$1.87▼$4.20Volume9,584 shsAverage Volume31,983 shsMarket Capitalization$20.99 millionP/E RatioN/ADividend YieldN/APrice Target$23.50Consensus RatingHold Company Overview Lisata Therapeutics, Inc. (NASDAQ: LSTA) is a clinical-stage biotechnology company focused on the discovery and development of novel therapies for severe diseases. The company’s pipeline comprises multiple product candidates in both preclinical and clinical stages, targeting autoimmune and inflammatory conditions through immunotherapeutic and cell-based approaches. Lisata’s research and development activities are designed to improve upon existing treatment modalities by emphasizing targeted biologics and precision cell therapies. To advance its programs, the company collaborates with academic institutions and contract research organizations, supporting clinical studies and translational research efforts in North America and Europe. Headquartered in the United States, Lisata Therapeutics is governed by a leadership team with experience in biotechnology research, clinical operations and regulatory affairs. The company’s board and scientific advisors bring expertise in immunology, drug development and commercial strategy to support its mission of addressing unmet medical needs.AI Generated. May Contain Errors. Read More Lisata Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks49th Percentile Overall ScoreLSTA MarketRank™: Lisata Therapeutics scored higher than 49% of companies evaluated by MarketBeat, and ranked 591st out of 958 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingHold Consensus RatingLisata Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialLisata Therapeutics has a consensus price target of $23.50, representing about 880.8% upside from its current price of $2.40.Amount of Analyst CoverageLisata Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Lisata Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Lisata Therapeutics are expected to grow in the coming year, from ($2.66) to ($2.36) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lisata Therapeutics is -1.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lisata Therapeutics is -1.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLisata Therapeutics has a P/B Ratio of 0.69. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Lisata Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.23% of the float of Lisata Therapeutics has been sold short.Short Interest Ratio / Days to CoverLisata Therapeutics has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Lisata Therapeutics has recently increased by 33.62%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLisata Therapeutics does not currently pay a dividend.Dividend GrowthLisata Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.23% of the float of Lisata Therapeutics has been sold short.Short Interest Ratio / Days to CoverLisata Therapeutics has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Lisata Therapeutics has recently increased by 33.62%, indicating that investor sentiment is decreasing significantly. News and Social Media2.1 / 5News Sentiment0.69 News SentimentLisata Therapeutics has a news sentiment score of 0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Lisata Therapeutics this week, compared to 2 articles on an average week. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Lisata Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.60% of the stock of Lisata Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 8.94% of the stock of Lisata Therapeutics is held by institutions.Read more about Lisata Therapeutics' insider trading history. Receive LSTA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lisata Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LSTA Stock News HeadlinesLisata Therapeutics Partners with Catalent on ADC TechnologyOctober 9 at 5:36 PM | finance.yahoo.comLisata Therapeutics Signs License Agreement with CatalentOctober 9 at 4:40 AM | msn.com$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because there's a $15 fund tied directly to gold's surge that's still paying massive income… Up to 64% annually — with payouts every 30 days.October 10 at 2:00 AM | Investors Alley (Ad)Lisata Therapeutics inks global product license deal with CatalentOctober 8 at 9:59 AM | proactiveinvestors.comLisata Therapeutics and Catalent Announce Global Antibody-Drug Conjugate (ADC) License AgreementOctober 8 at 8:30 AM | globenewswire.comIs Lisata Therapeutics (NASDAQ:LSTA) In A Good Position To Invest In Growth?October 3, 2025 | finance.yahoo.comLisata Therapeutics Highlights Preliminary Data in Pancreatic Cancer StudyOctober 1, 2025 | finance.yahoo.comLisata Therapeutics reveals 'encouraging' preliminary data from pancreatic cancer treatment trialSeptember 29, 2025 | proactiveinvestors.comSee More Headlines LSTA Stock Analysis - Frequently Asked Questions How have LSTA shares performed this year? Lisata Therapeutics' stock was trading at $2.98 at the beginning of the year. Since then, LSTA shares have decreased by 19.6% and is now trading at $2.3960. How were Lisata Therapeutics' earnings last quarter? Lisata Therapeutics, Inc. (NASDAQ:LSTA) issued its quarterly earnings data on Thursday, August, 7th. The company reported ($0.54) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.65) by $0.11. The company earned $0.07 million during the quarter. Read the conference call transcript. How do I buy shares of Lisata Therapeutics? Shares of LSTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Lisata Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Lisata Therapeutics investors own include PayPal (PYPL), JD.com (JD), NIO (NIO), Construction Partners (ROAD), Sunrun (RUN), ASE Technology (ASX) and Coinbase Global (COIN). Company Calendar Last Earnings8/07/2025Today10/10/2025Next Earnings (Estimated)11/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:LSTA CIK320017 Webwww.caladrius.com Phone(908) 842-0100Fax646-514-7787Employees30Year FoundedN/APrice Target and Rating Average Price Target for Lisata Therapeutics$23.50 High Price Target$32.00 Low Price Target$15.00 Potential Upside/Downside+867.1%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($2.23) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$19.99 million Net MarginsN/A Pretax Margin-1,858.41% Return on Equity-69.68% Return on Assets-59.44% Debt Debt-to-Equity RatioN/A Current Ratio5.77 Quick Ratio5.77 Sales & Book Value Annual Sales$1 million Price / Sales21.29 Cash FlowN/A Price / Cash FlowN/A Book Value$3.49 per share Price / Book0.70Miscellaneous Outstanding Shares8,760,000Free Float7,915,000Market Cap$21.29 million OptionableNot Optionable Beta1.04 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:LSTA) was last updated on 10/10/2025 by MarketBeat.com Staff From Our PartnersREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lisata Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lisata Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.